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Introducing The Cell Sheet Tissue 
Engineering Center at the University of 
Utah（CSTEC@Utah）
The Cell Sheet Tissue Engineering Center at 
the University of Utah（CSTEC@Utah）was 
established in 2015 by Professor Teruo 
Okano and Professor David Grainger. This 
center represents an ongoing collaboration 
between the University of Utah in Salt Lake 
City, Utah and the Tokyo Women's Medical 
University and Waseda University Joint 
Institute of Advanced Biomedical Sciences
（TWIns）in Tokyo, Japan. 
The goal of CSTEC@Utah is to develop 
novel, off-the-shelf regenerative treatments 
using allogeneic cell sheet technology to 
address critical unmet needs in regenerative 
medicine. CSTEC@Utah is currently working 
towards f irst - in-human trials ,  driving 
commercialization, and establishing itself as a 
Center of Excel lence in regenerat ive 
medicine. This center was founded to build 
on the success of CSTEC in Japan, by 
expanding the global influence through 
opportunities available in the US. Our current 
research focuses on applications for treating 
acute cartilage defects in the knee and 
infarcted cardiac tissue. Our team is using a 
variety of mesenchymal stem cells, including 
a Utah-patented cell line derived from 
umbilical cord tissue. This cell l ine is 
particularly interesting as an allogeneic 
source, as the cells are readily available, 
robust, proliferate rapidly, and have many 
favorable immunomodulatory characteristics.
Our CSTEC@Utah team currently consists of 
nine key members: 
Professor Teruo Okano, is a Co-director of 
CSTEC@Utah and a pioneer of cell sheet 
technology. He is a distinguished adjunct 
pro fessor  in  the  Univers i ty  o f  Utah 
Dep a r tmen t  o f  Ph a rmac eu t i c s  a nd 
Pharmaceutical Chemistry.
Professor David Grainger is a Co-director of 
CSTEC@Utah, a University Distinguished 
P r o f e s s o r  i n  P h a r m a c e u t i c s  a n d 
Pharmaceutical Chemistry, Chair of the 
Department of Biomedical Engineering, and a 
Professor of Bioengineering at the University 
of Utah in Salt Lake City, Utah. 
Professor Mime Egami  is an adjunct 
professor at the University of Utah. She is 
also a key leader of the CSTEC@Utah and 
has been acting as Chief Medical Innovation 
Officer and Visiting Professor at the Tokyo 
Women's Medical University for 10 years. 
Dr. Kyungsook Kim is a research assistant 
pro fessor  in  the  Univers i ty  o f  Utah 
Dep a r tmen t  o f  Ph a rmac eu t i c s  a nd 
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Pharmaceutical Chemistry and has been 
instrumental in transitioning her experience 
and knowledge from TWIns to the new 
center at Utah.
Dr. Goro Kuramoto is a visiting scientist at 
the University of Utah in the Department of 
Pha rmaceu t i c s  and  Pha rmaceu t i c a l 
Chemistry. He joined the team in May of 
2017 and is focusing on using cell sheets to 
treat and prevent uterine fibrosis.
Dr. Manshu Tang is a post-doctoral fellow at 
the University of Utah in the Department of 
Pha rmaceu t i c s  and  Pha rmaceu t i c a l 
Chemistry. He joined the team in May of 
2017 and is focusing on articular cartilage 
regeneration using allogeneic polydactyly cell 
sheets.
Nakao Mitsuyoshi was a visiting masters 
student from Keio University, who worked in 
Utah with our team for one year before 
returning to Keio in October 2017.
Soph i a  Bou -Ghannam  i s  a  3 rd  yea r 
bioengineering PhD student. The focus of her 
thesis research is cardiac regeneration using 
allogeneic cell sheet approaches. Sophia 
rece ived the Whitaker Internat iona l 
Fellowship in 2017/2018 and will be traveling 
to Tokyo at the end of this year to continue 
her research at TWIns.
I’m Hallie Thorp, and I am also a 3rd year 
bioengineering PhD student on the CSTEC@
Utah team. My project aims to create a less 
invasive, more affordable, and more robust 
therapy that can regenerate hyaline articular 
cartilage at the site of acute knee cartilage 
defects. The goal of my research is to use cell 
sheet technology, combined with allogeneic 
cell sourcing, to develop this next generation 
cartilage repair therapy. 
In May of 2016 I was awarded the Whitaker 
International Fellowship for 2016/2017, which 
is in part supporting my year of international 
research at TWIns under the guidance of 
Professor Takanori Iwata. The Whitaker 
International Fellowship supports sending 
emerging leaders  in  U .S .  b iomedica l 
engineering overseas to undertake a self-
designed project that will enhance their 
careers within the field.  The goal of the 
program is to assist the development of 
professional leaders who are not only superb 
scientists, but who also will advance the 
profession through an international outlook. 
In addition to support from the Whitaker 
Fellowship, the Yanagihara grant helps fund 
supplementary research materials and 
facilitates the high level of research available 
to me at TWIns. I am fortunate to have 
received this funding as it allows me to more 
freely explore all of my experimental ideas. 
My research plan for my year at TWIns 
consists of  both in vitro and in vivo 
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experimentation. An important first step is to 
understand how a cell sheet chondrogenically 
d i f ferent iates in v i tro .  Chondrogenic 
differentiation can be profiled and analyzed 
by  h i s t o l ogy ,  gene  expre s s i on ,  and 
biochemical analysis, which focus on Collagen 
II, Sox9, and Aggrecan production in addition 
to structural characteristics. By analyzing 
profiles of cell sheets at various stages of 
intermediate differentiation, it is possible to 
define stages of cell sheet chondrogenesis 
and thus predict the most therapeutically 
relevant cell sheet for in vivo regeneration. It 
is my hypothesis that a cell sheet that has 
been differentiated in vitro to an intermediate 
stage of chondrogenesis will have positive 
characteristics of both stem cells and 
chondrocytes ,  render ing i t  the most 
therapeutically beneficial cell sheet in vivo. 
Currently my project focuses on creating 
these differentiation profiles and defining 
stages of chondrogenic sheet differentiation 
f o r  h uman  umb i l i c a l  c o r d  d e r i v e d 
mesenchymal stem cells（hUC-MSCs）, which 
will later be used in a small animal model to 
further validate therapeutic effect. 
Personally, I have benefitted greatly from my 
time at TWIns. I have been able to make 
many friends and gain a global perspective of 
laboratory research. I have found the other 
students and staff at TWIns to be very kind, 
generous, and always willing to help as I 
learn my way around the new lab. I am also 
very fortunate to have the guidance and 
hospitality of Professor Iwata and the rest of 
his research team during my time in Japan. I 
am excited to continuing growing and 
learning from my new team during the rest 
of my time here.
The First  G loba l  Ce l l  Sheet  Cl in ica l 
Translation Symposium
The First Global Symposium for translating 
cell sheet engineering technology from 
research laboratories to the clinic was hosted 
by the University of Utah in July of 2017. 
Key opinion leaders in many fields and areas 
of focus, including both academia and 
industry, attended this three-day symposium. 
The CSTEC@Utah group was honored to 
host 2007 Nobel Laureate Mario Capecchi. 
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Dr. Capecchi spoke about the use and design 
o f  t r a n sg en i c  kn o ck ou t  a n ima l s  i n 
translational research. Opening remarks were 
made by Professor Randy Peterson （Dean of 
Pharmacy at the University of Utah）, Willard 
D e r e（ E x e c u t i v e  D i r e c t o r  o f  U t a h 
Personalized Health）, Ivy Eastabrooke
（USTAR Executive Director）, and Professor 
David Grainger. Plenary lectures were given 
by Professor Teruo Okano, Professor Tatsuya 
Shimizu（TWIns, TWMU）, Professor Song 
Cheol Kim（AMC）, Professor Matti Nikkola
（Karolinska Institute）, and Professor Masato 
Sato（Tokai University）. The symposium was 
divided into four sessions: cell sheet tissue 
engineering designs, clinical examples of 
regeneration in humans, regenerative 
therapy commercialization, and regulatory 
and outcomes assessment. In addition to the 
talks and lectures, Professor David Grainger 
headed a panel discussion focused on the 
future direction and challenges facing cell 
sheet technology. The panel consisted of 
Joanna Reems, S. Hashimoto, Diana Brixner, 
Mime Egami, D. Bora, and K. Slone. Since the 
conclusion of the symposium, the CSTEC@
Utah team has received very positive 
feedback and is looking forward to the next 
Global Cell Sheet Symposium. 
As a team, CSTEC@Utah has accomplished a 
great deal in the short amount of time since 
its founding. Our research focuses are 
constantly growing as we acquire new team 
members and new clinical collaborators. 
Currently we are focused on cardiac 
regeneration, articular cartilage regeneration, 
and have recently expanded to include 
treatment and prevention of uterine fibrosis. 
The team is actively pursuing a patent and 
has been awarded a large grant from the 
state of Utah to advance our projects and the 
mission of CSTEC@Utah. We look forward to 
growing our team and building on our 
international collaborations in the years to 
come. 
If you have more questions or would like to 
learn more about our group, please visit our 
website at www.cstecutah.com or email me 
directly at hallie.thorp@utah.edu. 
